CASP7 and cancer: RNA-binding protein MBNL2 (muscleblind-like splicing regulator 2) has shown to contribute to the post-transcriptional gene dysregulation in renal cell carcinoma [49], while loss-of-function mutations of CASP7 (caspase 7) contributed to cancer pathogenesis, representing an important prognostic and therapeutic target for several solid cancers [50].